Europe

The 26 research institutions have run nearly 4,600 trials testing medicines and, so far, 641 sets of results have been made available.

NICE has announced on Tuesday that for the first time in 20 years, a new treatment will be made available on the NHS for sickle cell disease.

The body in charge of pricing and reimbursement in Germany has downgraded the extent of additional benefit offered by Gilead’s Veklury for treating COVID-19 patients.

As part of its work to create a future-proof and crisis-resilient regulatory framework for the pharmaceutical sector, the Commission has published a public consultation on the revision of the EU's pharmaceutical legislation.

At the technical briefing, a new vision for collaboration between the public and private sectors was put forward to provide better access to safe, effective, novel, high-priced medicines.

Undeniably, COVID19 illustrates and emphasizes the urgent need to further increase transparency in pharmaceuticals, and to strengthen collaboration amongst Member States.

The U.K. government is now tracking whether clinical trial sponsors are reporting results, the latest sign that transparency campaigns are forcing greater disclosure by universities and companies.

NICE has updated its guidelines on the management of type 2 diabetes, recommending wider use of SGLT2 inhibitors in those with or at high-risk of cardiovascular disease (CVD).

A baby who received the world's most expensive drug four weeks ago has made "huge" progress, his parents said.

The health service will make the new treatment, inclisiran, available to 300,000 patients with high cholesterol and a history of cardiovascular disease over the next three years.

The EU and UK-Swedish drug-maker AstraZeneca have settled a row over a shortfall in coronavirus vaccines that affected the European rollout earlier this year.

The dispute plunged the European Union into crisis earlier this year as states, under pressure to speed up vaccinations, scrambled for shots. It also caused a public relations crisis for AstraZeneca, which is led by Frenchman Pascal Soriot.

A panel of regulators overseeing the implementation of several big data projects within the EU medicines network has given details of real-world evidence integration pilots to be undertaken next year.

The National Institute for Health and Care Excellence (NICE) has recommended Novartis’ interleukin-17A (IL-17A) inhibitor Cosentyx (secukinumab) for the treatment of children and young people with moderate-to-severe psoriasis.

IQWiG, Germany’s health technology appraisal institute, has found that Novartis’s gene therapy Zolgensma offers no additional benefit compared with Biogen’s Spinraza for treating spinal muscular atrophy.